Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antigenic link between human interferons-alpha and -beta: the common epitope 1.

P Kontsek1, L Borecký, E Kontseková

  • 1Institute of Virology, Slovak Academy of Sciences, Bratislava, Czechoslovakia.

Journal of Interferon Research
|April 1, 1990
PubMed
Summary

Researchers discovered a shared antigenic structure, "common epitope 1," on human interferon-alpha 2 (IFN-alpha 2) and interferon-beta (IFN-beta). This finding reveals antigenic similarities between these human interferon types.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development.

The journal of prevention of Alzheimer's disease·2018
Same author

Immunosenescence - the role in the immunotherapy of older population.

Bratislavske lekarske listy·2018
Same author

Prion protein prevents heavy metals overloading of cells and thus protects them against their toxicity.

Acta virologica·2015
Same author

Cytokines in health and disease.

World journal of microbiology & biotechnology·2014
Same author

Establishment of the cell line expressing human prion protein on PrP0/0 background.

Acta virologica·2010
Same author

Chronic wasting disease.

Acta virologica·2009

Area of Science:

  • Immunology
  • Virology
  • Biochemistry

Background:

  • Human interferons (IFNs) are crucial cytokines with diverse antiviral and immunomodulatory functions.
  • IFN-alpha and IFN-beta are type I interferons, historically distinguished by distinct antigenic properties.
  • Understanding interferon epitopes is vital for developing targeted therapies and diagnostics.

Purpose of the Study:

  • To identify and characterize previously unobserved antigenic structures shared between human recombinant IFN-alpha 2 (rHuIFN-alpha 2) and natural human IFN-beta (HuIFN-beta).
  • To investigate the molecular basis of any shared antigenic epitopes between IFN-alpha 2 and IFN-beta.
  • To determine if the antigenic distinction between alpha and beta type human interferons is absolute.

Main Methods:

Related Experiment Videos

  • Testing with monoclonal and polyclonal antibodies against rHuIFN-alpha 2 and HuIFN-beta.
  • Utilizing antibody B6, raised against HuIFN-beta, for binding and neutralization assays.
  • Employing synthetic hexapeptides corresponding to specific amino acid sequences for inhibition studies.
  • Performing cross-neutralization experiments with antisera to IFN-alpha 2 and IFN-beta.

    • Main Results:

    • A consistent antigenic structure,
    • common epitope 1,
    • was detected on both rHuIFN-alpha 2 and HuIFN-beta.
    • Monoclonal antibody B6 neutralized both IFN-alpha 2 and IFN-beta, with activity inhibited by an IFN-alpha 2 specific hexapeptide.
    • Lysine at position 132 (IFN-alpha 2) and 134 (IFN-beta) appears crucial for the common epitope.
    • Polyclonal antisera demonstrated cross-neutralization between IFN-alpha 2 and IFN-beta, abolished by the IFN-alpha 2 hexapeptide.
    • No cross-reacting epitope was found on IFN-alpha 1.

    Conclusions:

    • These findings provide the first evidence of antigenic homology between human IFNs of the alpha and beta types.
    • The antigenic distinction between human IFN-alpha and IFN-beta is not absolute, challenging previous assumptions.
    • The identified common epitope suggests potential for cross-reactive therapeutic antibodies or diagnostic tools.